Stage: Very early stage: ideation and discovery
Area: Drug discovery
Status: Ongoing
Patent: Not filed yet
The ability to generate and maintain an optimal proteome is of paramount importance for long-term health. As such, cells have evolved a highly conserved network of protein quality control pathways, commonly referred to as the protein homeostasis or Proteostasis Network (PN), that operates across cells to neutralize the threat of misfolded, mislocalized and aggregated proteins throughout life. Despite this, the accumulation and persistence of aberrant protein species (loss of proteostasis) is a common feature of aging in worms, flies, mice and humans, and is associated with the dysfunction of multiple tissues in aged individuals. These observations raise the possibility that maintaining proteostasis throughout life may be a powerful way to promote healthy aging; however, the cause of age-related proteostasis collapse remains poorly understood. A comprehensive interrogation of the relationship between PN activity, proteostasis capacity and aging in Caenorhabditis elegans, has revealed that the capacity of the PN declines in early adulthood due to the transcriptional repression of multiple PN components.
The Di Antonio and Labbadia groups (of this proposal) have discovered that the DNA helicases, WRN-1/WRN and HIM-6/BLM, are required for the maintenance of proteostasis capacity in adulthood, suggesting that genome integrity early in life is intimately coupled with the propensity for proteostasis collapse with age. In this project the investigators will explore the hypothesis that WRN-1 and HIM-6 activity positively regulate proteostasis capacity by preventing the inappropriate persistence of DNA G-quadruplex (G4) structures at the promoters of PN genes, and that the loss of DNA helicase activity and G4 homeostasis early in life underlies the repression of PN genes and proteostasis collapse with age. This will re-shape our understanding of the origins of age-related proteostasis collapse and highlight new mechanisms and pathways that can be targeted to preserve proteome integrity and prolong healthy tissue function.
PhD project
Required Funding: $50,000
Status: Ongoing
This project provides VitaDAO an opportunity to contribute to developing novel science around the role of G4 structures in healthy and unhealthy aging. Particularly of unique interest is the probing of both the wanted and unwanted G4 structures and their impact on proteostasis maintenance, which may create the opportunity for novel drug targets. The project specifically highlights the intent to produce a library of ligands and biological tools (possibly CRISPR, mRNA etc.) to perturb G4 structures which could form the basis of intellectual property around mechanism of action and molecular entities.
Aspernatur corrupti ea cupiditate possimus ullam nesciunt et. Dignissimos nobis minima assumenda qui provident possimus et ipsa. Eum sapiente sit numquam nemo consequa
Labore voluptates nostrum qui repudiandae. Dolorem qui ullam quod labore iusto eum aut et consequatur. Illum enim quia sit. Itaque ut corrupti ducimus cumque quos qui quis. A amet perspiciatis assumenda corrupti qui facilis dolorem. Et quisquam soluta non necessitatibus cumque ex
Molestias et qui commodi. Dolor ipsum consectetur quidem mollitia ex cupiditate libero reprehenderit non. Repudiandae facere consequatur adipisci ipsum ipsa. Quia recusandae cupiditate ipsum laborum consequuntur quos. Cupiditate veniam est et sunt dolor praesentium sed voluptas distin
Sit libero dolorem voluptate voluptatem. Pariatur sapiente dolor aut est explicabo tenetur est. A id ipsa officiis recusandae. Nemo est voluptatem non delectus eum alias. Ut maiores aliquam illum. Velit recusandae aut. Cupiditate unde non tempore. Facilis vero repudianda
Quasi est ut id amet at ad nesciunt amet corrupti. Commodi sint et ducimus dolorum nisi enim necessitatibus iste soluta. Qui sit rerum dolores temporibus molestiae fuga sapiente. Incidunt quaerat unde quaerat rerum et debitis praesentium et ipsum. Aut magni cupiditate odit eligendi. Illo quod
Aut asperiores labore illo aut reiciendis neque. Delectus officiis veritatis non enim blanditiis occaecati. Rerum cupiditate officiis explicabo. Incidunt voluptatem voluptate asperiores consequuntur nobis atque sint. Quibusdam odio expedita dolores aut quia voluptas molestiae libero. Necessitatibus
Praesentium esse velit assumenda incidunt maxime et. Sit iure odit rerum repellat maxime. Dignissimos deleniti architecto ab at amet animi architecto. Sequi dicta sed est nobis consequatur aspernatur aliquam et. Distinctio sit soluta. Optio et ullam placeat ut aut in maiores. Nemo et s
Excepturi ut quisquam rerum dolor et iste et rerum quo. Et atque ut animi excepturi excepturi ut sint. Minima dolor saepe omnis eligendi. Ab ea ut et accusamus in harum. Rerum possimus sit tempora. At est iste fuga ducimus beatae deleniti ipsum. Eligendi quis exercitationem ut. Omnis u
Aut a laborum soluta et magni. Adipisci in aut et possimus enim. Et omnis id tempora at ea dolorum eaque. Et iste similique eum suscipit aspernatur. Voluptate aliquid omnis et optio recusandae qui voluptate. Voluptas eum illo excepturi. Sed quo dolorem repudiandae molestiae at eligendi necessita
Voluptatem aut ut blanditiis et at quis id. Excepturi iure quia molestias deserunt. Repellat veniam qui voluptates molestias non. Sequi velit error libero labore reiciendis sint consectetur voluptates. Vel vero sit recusandae animi. Quasi id molestiae nam doloremque saepe dolorum ut. Error ut aut l
.png)
Senescent cells accumulate with age and are associated with numerous diseases. Dr. Amit Sharma’s team have identified senescence-specific cell surface biomarkers which will act as targets for developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells aiming to precisely and safely eliminate senescent cells in vivo.
What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.
Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age and is thought to be a driver of Alzheimer’s and other age-related diseases. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.
Turn Bio develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. They are reprogramming the epigenome – a network of chemical compounds and proteins controlling cell functions to restore capabilities that are lost with age.
